SUNDAY, MARCH 21
Arrival and Registration

MONDAY, MARCH 22
Welcome and Keynote Session (Joint)
Helen H. Hobbs, University of Texas Southwestern Medical Center, USA
PNPLA3’s Role in NAFLD

Hashem B. El-Serag, Baylor College of Medicine, USA
Changing Epidemiological Trends in Non-Alcoholic Fatty Liver Disease versus Viral-Associated Hepatobiliary Cancers

Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint)
Lopa Mishra, George Washington University, USA
TGF-beta Signaling in Liver Fibrosis and Hepatocellular Carcinoma

Speaker to be Announced
Short Talks Chosen from Abstracts

Genetics of NAFLD (X5)
Elizabeth K. Speliotes, University of Michigan, USA
Use of GWAS to Identify SNPs Associated with NAFLD

Hannele Yki-Järvinen, University of Helsinki, Finland
Effects of Genetic Risk Factors for NAFLD on Hepatic Lipid Metabolism

Noura S. Abul-Husn, Icahn School of Medicine at Mount Sinai, USA
HSD17B13 and Protection from Liver Disease in Diverse Patient Populations

Short Talks Chosen from Abstracts

Tumor Microenvironment and Hepatobiliary Cancers (X6)
Silvia Affo, Columbia University, USA
The Role of Cancer-Associated Fibroblasts in the Pathogenesis of Hepatobiliary Cancers

Amaia Lujambio, Icahn School of Medicine at Mount Sinai, USA
Mechanisms of Immune Escape in Hepatocellular Carcinoma

Alphonse E. Sirica, Virginia Commonwealth University, USA
The Desmoplastic Reaction in Intrahepatic Cholangiocarcinoma: Molecular Drivers and Prognostic Implications

Gregory J. Gores, Mayo Clinic, USA
Targeting the Tumor Microenvironment for Cholangiocarcinoma Therapy

Short Talks Chosen from Abstracts

NAFLD and CVD (X5)
Speaker to be Announced

Jay D. Horton, University of Texas Southwestern Medical Center, USA
Molecular Mediators of NAFLD and Hyperlipidemia

Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA
Loss of Function of TorsinA, an ER Localized AAA ATPase Causes Severe Steatosis with Decreased VLDL Secretion and Abnormal ER Lipid Droplets

Short Talks Chosen from Abstracts

Hepatobiliary Cancer Biomarkers (X6)
Yujin Hoshida, UT Southwestern Medical Center, USA
Liver Cancer Risk-Predictive Molecular Biomarkers Specific to Clinico-Epidemiological Contexts

Irene Oi Lin Ng, University of Hong Kong, Hong Kong
Molecular Biomarkers in Hepatocellular Carcinoma

TUESDAY, MARCH 23
Role of Lipids in NAFLD (X5)
Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA
Circadian Contributions to NAFLD

Daniel A. Heller, Memorial Sloan Kettering Cancer Center, USA
Lipid Dysregulation in Inflammation, NASH, and Cancer

Catherine Postic, INSERM, Institut Cochin, France
Altered Insulin Signaling and Glucose Toxicity in NAFLD

Tobias C. Walther, Harvard School of Public Health, USA
Lipid Droplet Biology in NAFLD

Short Talks Chosen from Abstracts

Poster Session 1
Augusto Villanueva Rodriguez, Icahn School of Medicine at Mount Sinai, USA
Liquid Biopsy in Hepatobiliary Cancers
Short Talks Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 24

Pathways to NASH (X5)

Speaker to be Announced
Mark A. McNiven, Mayo Clinic, USA
Lipid Droplet Formation and Lipophagy in Fatty Liver Disease
Eran Elinav, Weizmann Institute of Science, Israel
Lipid-Associated Macrophages Control Metabolic Homeostasis

Speaker to be Announced
Short Talks Chosen from Abstracts

Genomic and Epigenomic Heterogeneity in Hepatobiliary Cancers (X6)

Xin Wei Wang, NCI, National Institutes of Health, USA
Causes and Functional Intricacies of Intertumor and Intratumor Heterogeneity in Primary Hepatobiliary Cancers
Jessica Zucman-Rossi, University Paris Descartes-HEGP, France
Molecular Subtypes of Hepatocellular Carcinoma are Related to Specific Tumor Phenotypes
Renumathy Dhanasekaran, Stanford University, USA
Complexities of Genetic Heterogeneity in Hepatocellular Carcinoma
Bin Tean Teh, Duke-NUS Medical School, Singapore
Cholangiocarcinoma in Diverse Populations

Short Talks Chosen from Abstracts

Emerging Therapies for NASH-I (X5)

Morris J. Birnbaum, Pfizer Inc., USA
DGAT2 Inhibition for NASH

Speaker to be Announced
Greg Steinberg, McMaster University, Canada
Cellular Energy Sensors and Metabolism

Short Talks Chosen from Abstracts

"Omics" for Precision Medicine of Hepatobiliary Cancers (X6)

Josep Llovet, Icahn School of Medicine at Mount Sinai, USA
Integrative "Omics" and Precision Medicine for Hepatocellular Carcinoma
Jesper Bøje Andersen, University of Copenhagen, Denmark
Defining Distinct Subtypes of Intrahepatic Cholangiocarcinoma by Molecular Profiling: Diagnostic, Prognostic, and Therapeutic Applications

Robert F. Schwabe, Columbia University, USA
Discovery of Subgroup-Specific HCC Master Regulators by Systems Biology Approaches

Short Talks Chosen from Abstracts

Emerging Therapies for NASH-II (X5)

Kendra K. Bence, Pfizer Inc., USA
Inhibition of Fructose Metabolism for the Treatment of NAFLD
Chuhan Chung, Gilead Sciences, USA
ACC Inhibitors for NASH
Lei Ling, NGM Biopharmaceuticals, USA
Therapeutic FGF19 in Non-Alcoholic Steatohepatitis

Short Talks Chosen from Abstracts

Advances in Molecular and Immune Targeting of Hepatobiliary Cancers (X6)

Bruno Sangro, Clinica Universidad de Navarra, Spain
Targeted Agent and Immune-Based Therapies for Hepatocellular Carcinoma
Tim F. Greten, NCI, National Institutes of Health, USA
Immunotherapies for Hepatobiliary Cancers: Current Status and Future Perspectives
R. Kate Kelley, University of California, San Francisco, USA
Developing Clinical Trials of Novel Therapeutic Agents and Treatment Combinations for Intrahepatic Cholangiocarcinoma

Short Talks Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X5)
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X6)

THURSDAY, MARCH 25

Departure